1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Clinical characteristics of the study population^{^a}
Variables Radionecrosis Recurrence Summary
Age (IQR) (yr) 58 (52.5–66) 59 (53–67) 58.5 (53–65.8)
Sex (M/F) 13:16 13:14 26:30
Primary tumor history 
    Lung (No.) (%) 18 (62.0) 16 (59.3) 34 (60.7)
    Digestive tract (No.) (%) 2 (6.9) 4 (14.8) 6 (10.6)
    Breast (No.) (%) 4 (13.8) 4 (14.8) 8 (14.3)
    Kidney (No.) (%) 2 (6.9) 2 (7.4) 4 (7.1)
    Skin (No.) (%) 3 (10.3) 1 (3.7) 4 (7.1)
Location 
    Occipital (No.) (%) 7 (24.1) 4 (14.8) 11 (19.6)
    Parietal (No.) (%) 5 (17.2) 7 (25.9) 12 (21.4)
    Frontal (No.) (%) 7 (24.1) 5 (18.5) 12 (21.4)
    Temporal (No.) (%) 3 (10.3) 2 (7.4) 5 (18.5)
    Cerebellum (No.) (%) 4 (13.8) 6 (22.2) 10 (37.0)
    Brain stem (No.) (%) 1 (3.4) 1 (3.7) 2 (7.4)
    Basal ganglia (No.) (%) 2 (6.9) 2 (7.4) 4 (14.8)
MD (median) (IQR) (cm) 2.2 (1.6–2.5) 2.5 (1.7–3.4) 2.3 (1.6–2.8)
Dose (median) (IQR) (Gy) 18 (18–21) 18 (18–21) 18 (18–21)
KPS (median) (IQR) 70 (70–90) 70 (60–90) 70 (70–90)
Note:—KPS indicates Karnofsky Performance Status Scale; MD, maximum diameters; IQR, interquartile range.
↵a Data are presented as descriptive statistics (median or count). Numbers in parentheses represent the range of data.